Biocon And Viatris Scoop EU Insulin Aspart Approval

Analyst Expects Biosimilar Penetration To Be ‘Slow And Minimal’

 
• By Dean Rudge
  
Europe_Map_Connection
Kixelle’s approval comes soon after Biocon announced the abrupt exit of Biocon Biologics’ CEO Christiane Hamacher • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin